Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1802185
Max Phase: Preclinical
Molecular Formula: C19H18ClNaO8
Molecular Weight: 410.81
Molecule Type: Small molecule
Associated Items:
ID: ALA1802185
Max Phase: Preclinical
Molecular Formula: C19H18ClNaO8
Molecular Weight: 410.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C([O-])c1ccc(-c2ccc(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(Cl)c2)cc1.[Na+]
Standard InChI: InChI=1S/C19H19ClO8.Na/c20-12-7-11(9-1-3-10(4-2-9)18(25)26)5-6-13(12)27-19-17(24)16(23)15(22)14(8-21)28-19;/h1-7,14-17,19,21-24H,8H2,(H,25,26);/q;+1/p-1/t14-,15-,16+,17+,19+;/m1./s1
Standard InChI Key: ANKKJQZHPLEHGC-DKNLRZDWSA-M
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 410.81 | Molecular Weight (Monoisotopic): 410.0768 | AlogP: 0.88 | #Rotatable Bonds: 5 |
Polar Surface Area: 136.68 | Molecular Species: ACID | HBA: 7 | HBD: 5 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.07 | CX Basic pKa: | CX LogP: 1.31 | CX LogD: -1.81 |
Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.49 | Np Likeness Score: 0.89 |
1. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.. (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation., 53 (24): [PMID:21105658] [10.1021/jm101011y] |
2. Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B.. (2012) Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success., 55 (10): [PMID:22519985] [10.1021/jm300192x] |
Source(1):